Recent years have seen exciting breakthroughs in biomedical sciences that are producing truly novel therapeutics for unmet patient needs. A paradigm shift in the operating business models of pharmaceutical companies is witnessed by the transition to a lean, focused company with a research footprint within key innovation bioclusters and a growing revenue stream from specialty products and biologics and, emerging markets.
With novel drug targets becoming more competitive, order of entry has become an increasingly important consideration for clinical-development decisions and commercial resourcing. First-mover advantage is more pronounced in specialty areas with small numbers of prescribers and patients and Injectable drugs have stronger first-mover effects than oral preparations.
In the midst of these exciting times for the pharmaceutical industry, you will find a resourceful partner in Xeina Drugs, that constantly endeavours to bring to you novel drugs to add to your portfolio and gain a first entry advantage.
Why license Specialised Products from Xeina Drugs
- Novel drugs portfolio, first entry generics
- EU approved facilities and EU CTD dossiers
- Bioequivalence studies for oral formulations
- Open for FDF supply